

Table 1.16

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity
Males, 18 SEER Areas, 2010-2012

| Site | All Races | | Whites | | Blacks | |
|--|-----------|------------------|---------|------------------|---------|------------------|
| | Percent | (95% C.I.) | Percent | (95% C.I.) | Percent | (95% C.I.) |
| All Sites | 42.05 | (41.92, 42.18) | 41.71 | (41.56, 41.85) | 40.77 | (40.37, 41.17) |
| Invasive and In Situ | 43.54 | (43.40, 43.67) | 43.21 | (43.07, 43.36) | 41.10 | (40.70, 41.51) |
| Oral Cavity and Pharynx | 1.55 | (1.53, 1.58) | 1.62 | (1.59, 1.64) | 1.18 | (1.12, 1.25) |
| Esophagus | 0.80 | (0.78, 0.82) | 0.84 | (0.82, 0.86) | 0.63 | (0.59, 0.69) |
| Stomach | 1.07 | (1.05, 1.09) | 0.97 | (0.95, 0.99) | 1.20 | (1.13, 1.28) |
| Colon and Rectum | 4.69 | (4.65, 4.74) | 4.57 | (4.53, 4.62) | 4.87 | (4.74, 5.02) |
| Invasive and In Situ | 4.87 | (4.83, 4.92) | 4.74 | (4.70, 4.79) | 5.11 | (4.97, 5.26) |
| Liver and Intrahepatic Bile Duct | 1.31 | (1.28, 1.33) | 1.16 | (1.14, 1.19) | 1.45 | (1.39, 1.52) |
| Pancreas | 1.54 | (1.51, 1.56) | 1.54 | (1.51, 1.57) | 1.49 | (1.41, 1.57) |
| Larynx | 0.59 | (0.57, 0.60) | 0.59 | (0.57, 0.60) | 0.75 | (0.70, 0.81) |
| Invasive and In Situ | 0.63 | (0.61, 0.64) | 0.63 | (0.61, 0.64) | 0.79 | (0.74, 0.85) |
| Lung and Bronchus | 7.19 | (7.14, 7.24) | 7.20 | (7.14, 7.26) | 7.52 | (7.34, 7.70) |
| Melanoma of the Skin | 2.62 | (2.58, 2.65) | 3.03 | (2.99, 3.07) | 0.10 | (0.08, 0.12) |
| Invasive and In Situ | 4.37 | (4.33, 4.41) | 4.94 | (4.89, 4.98) | 0.13 | (0.11, 0.16) |
| Breast | 0.13 | (0.12, 0.14) | 0.13 | (0.12, 0.14) | 0.16 | (0.14, 0.19) |
| Invasive and In Situ | 0.14 | (0.14, 0.15) | 0.14 | (0.13, 0.15) | 0.18 | (0.16, 0.21) |
| Prostate | 13.97 | (13.89, 14.04) | 13.15 | (13.07, 13.23) | 18.15 | (17.90, 18.41) |
| Testis | 0.38 | (0.38, 0.39) | 0.46 | (0.44, 0.47) | 0.10 | (0.09, 0.12) |
| Urinary Bladder (Invasive and In Situ) | 3.84 | (3.80, 3.88) | 4.16 | (4.12, 4.21) | 1.86 | (1.77, 1.96) |
| Kidney and Renal Pelvis | 2.03 | (2.01, 2.06) | 2.09 | (2.06, 2.12) | 1.96 | (1.88, 2.04) |
| Brain and Other Nervous System | 0.69 | (0.68, 0.71) | 0.76 | (0.74, 0.78) | 0.40 | (0.36, 0.44) |
| Thyroid | 0.59 | (0.58, 0.60) | 0.63 | (0.62, 0.65) | 0.27 | (0.25, 0.31) |
| Hodgkin Lymphoma | 0.24 | (0.23, 0.25) | 0.25 | (0.24, 0.26) | 0.21 | (0.19, 0.24) |
| Non-Hodgkin Lymphoma | 2.37 | (2.34, 2.40) | 2.47 | (2.44, 2.51) | 1.43 | (1.36, 1.50) |
| Myeloma | 0.85 | (0.84, 0.87) | 0.81 | (0.79, 0.83) | 1.33 | (1.26, 1.41) |
| Leukemia | 1.75 | (1.73, 1.78) | 1.84 | (1.81, 1.87) | 1.14 | (1.07, 1.21) |
| Acute Lymphocytic Leukemia | 0.14 | (0.14, 0.15) | 0.16 | (0.15, 0.16) | 0.08 | (0.07, 0.10) |
| Chronic Lymphocytic Leukemia | 0.69 | (0.67, 0.71) | 0.73 | (0.71, 0.74) | 0.43 | (0.39, 0.49) |
| Acute Myeloid Leukemia | 0.53 | (0.52, 0.55) | 0.55 | (0.53, 0.57) | 0.36 | (0.32, 0.40) |
| Chronic Myeloid Leukemia | 0.22 | (0.21, 0.23) | 0.23 | (0.22, 0.24) | 0.15 | (0.12, 0.17) |
| Kaposi Sarcoma | 0.08 | (0.07, 0.08) | 0.06 | (0.06, 0.07) | 0.16 | (0.14, 0.18) |
| Mesothelioma | 0.20 | (0.19, 0.21) | 0.22 | (0.21, 0.23) | 0.09 | (0.07, 0.12) |

Devcan Version 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Males, 18 SEER Areas, 2010-2012

| Site | Asian/Pacific Islanders | American Indian/ Alaska Natives ^a | Hispanics ^b |
|--|----------------------------|---|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 36.15 (35.64, 36.68) | 28.31 (26.68, 30.15) | 38.84 (38.37, 39.33) |
| Invasive and In Situ | 36.48 (35.97, 37.01) | 28.61 (26.97, 30.46) | 39.29 (38.81, 39.78) |
| Oral Cavity and Pharynx | 1.21 (1.12, 1.31) | 1.37 (1.05, 1.95) | 1.12 (1.05, 1.21) |
| Esophagus | 0.55 (0.48, 0.63) | 0.42 (0.27, 0.91) | 0.62 (0.57, 0.69) |
| Stomach | 2.05 (1.92, 2.20) | 1.43 (1.06, 2.07) | 1.70 (1.60, 1.82) |
| Colon and Rectum | 5.27 (5.07, 5.48) | 4.42 (3.80, 5.26) | 4.72 (4.56, 4.90) |
| Invasive and In Situ | 5.44 (5.24, 5.65) | 4.48 (3.86, 5.33) | 4.87 (4.71, 5.05) |
| Liver and Intrahepatic Bile Duct | 2.56 (2.43, 2.70) | 1.76 (1.40, 2.37) | 2.25 (2.15, 2.37) |
| Pancreas | 1.58 (1.48, 1.70) | 1.20 (0.84, 1.85) | 1.50 (1.40, 1.62) |
| Larynx | 0.33 (0.28, 0.40) | 0.33 (0.20, 0.81) | 0.53 (0.47, 0.60) |
| Invasive and In Situ | 0.38 (0.32, 0.45) | 0.36 (0.22, 0.83) | 0.56 (0.50, 0.63) |
| Lung and Bronchus | 6.81 (6.57, 7.05) | 4.85 (4.16, 5.78) | 4.80 (4.61, 5.01) |
| Melanoma of the Skin | 0.20 (0.17, 0.26) | 0.29 (0.17, 0.77) | 0.51 (0.46, 0.58) |
| Invasive and In Situ | 0.30 (0.25, 0.37) | 0.50 (0.33, 0.99) | 0.80 (0.73, 0.89) |
| Breast | 0.08 (0.06, 0.13) | 0.03 (0.01, 0.50) | 0.08 (0.06, 0.12) |
| Invasive and In Situ | 0.09 (0.07, 0.14) | 0.05 (0.02, 0.53) | 0.09 (0.07, 0.13) |
| Prostate | 9.39 (9.15, 9.64) | 6.53 (5.81, 7.48) | 12.96 (12.71, 13.22) |
| Testis | 0.15 (0.13, 0.18) | 0.32 (0.24, 0.76) | 0.35 (0.33, 0.39) |
| Urinary Bladder (Invasive and In Situ) | 2.34 (2.20, 2.50) | 1.67 (1.21, 2.42) | 2.58 (2.44, 2.74) |
| Kidney and Renal Pelvis | 1.39 (1.30, 1.49) | 2.21 (1.83, 2.83) | 2.14 (2.03, 2.25) |
| Brain and Other Nervous System | 0.45 (0.40, 0.52) | 0.35 (0.24, 0.81) | 0.55 (0.51, 0.61) |
| Thyroid | 0.61 (0.56, 0.68) | 0.35 (0.24, 0.81) | 0.48 (0.44, 0.53) |
| Hodgkin Lymphoma | 0.14 (0.12, 0.18) | 0.10 (0.04, 0.57) | 0.23 (0.20, 0.28) |
| Non-Hodgkin Lymphoma | 2.09 (1.98, 2.23) | 1.37 (1.05, 1.95) | 2.39 (2.28, 2.51) |
| Myeloma | 0.62 (0.55, 0.70) | 0.49 (0.28, 1.03) | 0.93 (0.85, 1.02) |
| Leukemia | 1.20 (1.11, 1.31) | 0.90 (0.64, 1.45) | 1.40 (1.31, 1.51) |
| Acute Lymphocytic Leukemia | 0.13 (0.11, 0.17) | 0.09 (0.05, 0.56) | 0.19 (0.18, 0.23) |
| Chronic Lymphocytic Leukemia | 0.27 (0.22, 0.34) | 0.20 (0.07, 0.70) | 0.36 (0.31, 0.43) |
| Acute Myeloid Leukemia | 0.52 (0.46, 0.59) | 0.29 (0.17, 0.77) | 0.49 (0.43, 0.56) |
| Chronic Myeloid Leukemia | 0.19 (0.16, 0.24) | 0.16 (0.07, 0.63) | 0.21 (0.18, 0.26) |
| Kaposi Sarcoma | 0.04 (0.03, 0.07) | 0.04 (0.00, 0.52) | 0.11 (0.09, 0.16) |
| Mesothelioma | 0.08 (0.06, 0.13) | 0.16 (0.06, 0.64) | 0.18 (0.16, 0.24) |

Devcan Version 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

^a Underlying incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.